Pathway overview
CAR-T cell therapy modifies a patient’s T cells to recognize a defined target on cancer cells. It is considered only for selected relapsed or refractory hematologic malignancies after detailed hematology or oncology review.
A diagnosis of leukemia, lymphoma or multiple myeloma does not by itself establish eligibility. The exact subtype, target expression, prior treatment, disease status, organ function, infection risk, product access and alternative therapies all require specialist assessment.
Important distinctions
- Selected indications
- CAR-T is not a general cancer treatment and is not appropriate for every blood cancer or every relapsed case.
- Multi-step pathway
- Review may include pathology confirmation, leukapheresis planning, cell manufacturing, bridging treatment, lymphodepletion, infusion and monitored follow-up.
- Specialist risk management
- Cytokine release syndrome, neurologic toxicity, infection, prolonged low blood counts and later complications require experienced monitoring.
Topics a hospital may evaluate
Requirements differ by person, programme, and jurisdiction. A licensed transplant team may consider:
- Confirmed hematologic diagnosis, subtype and target
- Prior therapies and response
- Current disease burden and clinical stability
- Organ function and infection status
- Potential alternatives and sequencing
- Cell collection and manufacturing feasibility
- Caregiver, travel and long-term follow-up planning
Questions to ask a licensed transplant hospital
- Is this exact disease and treatment history suitable for CAR-T evaluation?
- Which target and product pathway, if any, is being considered?
- What alternatives should be compared before proceeding?
- How will urgent toxicities and prolonged immune effects be monitored?
- What care must be coordinated after returning home?